Global Biopharmaceuticals Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Biopharmaceuticals Contract Manufacturing Market is presumed to reach the market size of nearly USD 33.92 Billion by 2032 from USD 19.74 Billion in 2023 with a CAGR of 6.2% under the study period 2024 - 2032.

Biopharmaceuticals contract manufacturing involves outsourcing the production of biopharmaceutical products to specialized contract manufacturers. These products include biologics such as monoclonal antibodies, vaccines, and recombinant proteins, which require complex manufacturing processes and stringent quality control. Contract manufacturing organizations (CMOs) provide services, including cell line development, process development, and large-scale production. This model allows biopharmaceutical companies to leverage the expertise and capabilities of CMOs, reducing the need for in-house manufacturing facilities and associated capital expenditures. Companies can focus on research and development by outsourcing production while benefiting from the CMOs' advanced technologies and regulatory compliance expertise.

Market Dynamics

The biopharmaceuticals contract manufacturing market is experiencing robust growth attributed to the rising demand for biologics & advanced therapeutics. Biopharmaceutical companies outsource manufacturing to specialized contract manufacturers to scale production capabilities and meet the growing market demand for complex biologic drugs, such as monoclonal antibodies and gene therapies. Biopharmaceutical production's high cost and complexity drive the need for contract manufacturing services. Contract manufacturers offer expertise in handling sophisticated production processes and maintaining stringent quality standards, which can be cost-prohibitive for individual companies to manage in-house. Biopharmaceutical firms can reduce capital investments and operational costs while accessing state-of-the-art manufacturing technologies by outsourcing.

Technological advancements in bio-manufacturing are creating new opportunities within the market. Innovations such as single-use technologies and continuous manufacturing processes enhance production efficiency and flexibility. These advancements enable faster turnaround times and reduced risk of contamination, making contract manufacturing an attractive option for biopharmaceutical companies. The emerging trend of personalized medicine is also contributing to the growth of the biopharmaceuticals contract manufacturing market. The need for small-batch, high-quality production of personalized therapeutics is well-suited to contract manufacturers' capabilities. Additionally, the expansion of the biotechnology sector and increasing investments in biopharmaceutical R&D are driving demand for contract manufacturing services. However, regulatory complexities and the risk of intellectual property theft may hinder biopharmaceuticals contract manufacturing market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biopharmaceuticals contract manufacturing. The growth and trends of biopharmaceuticals contract manufacturing industry provide a holistic approach to this study.

Market Segmentation

This section of the biopharmaceuticals contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

Mammalian
Non-mammalian

By Service

Process Development (Downstream, Upstream)
Fill & Finish Operations
Analytical & QC Studies
Packaging

By Product

Biologics (Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others)
Biosimilars
Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Biopharmaceuticals Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS Pharma, AGC Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Toyobo Co., Ltd., Samsung BioLogics, Thermo Fisher Scientific, Inc., Binex Co., Ltd., WuXi Biologics, AbbVie, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11214545

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BIOPHARMACEUTICALS CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Source
- 3.7.2 By Service
- 3.7.3 By Product
- 3.7.4 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET ANALYSIS BY SOURCE

6.1 Overview by Source
6.2 Historical and Forecast Data
6.3 Analysis by Source
6.4 Mammalian Market by Regions
6.5 Non-mammalian Market by Regions

7 . GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET ANALYSIS BY SERVICE

7.1 Overview by Service
7.2 Historical and Forecast Data
7.3 Analysis by Service
7.4 Process Development Market by Regions
7.5 Fill & Finish Operations Market by Regions
7.6 Analytical & QC Studies Market by Regions
7.7 Packaging Market by Regions

8 . GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT

8.1 Overview by Product
8.2 Historical and Forecast Data
8.3 Analysis by Product
8.4 Biologics Market by Regions
8.5 Biosimilars Market by Regions

9 . GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America
- 9.3.1. Overview, Historic and Forecast Data
- 9.3.2. North America By Segment
- 9.3.3. North America By Country
- 9.3.4. United State
- 9.3.5. Canada
- 9.3.6. Mexico
9.4. Europe
- 9.4.1. Overview, Historic and Forecast Data
- 9.4.2. Europe by Segment
- 9.4.3. Europe by Country
- 9.4.4. United Kingdom
- 9.4.5. France
- 9.4.6. Germany
- 9.4.7. Italy
- 9.4.8. Russia
- 9.4.9. Rest Of Europe
9.5. Asia Pacific
- 9.5.1. Overview, Historic and Forecast Data
- 9.5.2. Asia Pacific by Segment
- 9.5.3. Asia Pacific by Country
- 9.5.4. China
- 9.5.5. India
- 9.5.6. Japan
- 9.5.7. South Korea
- 9.5.8. Australia
- 9.5.9. Rest Of Asia Pacific
9.6. Latin America
- 9.6.1. Overview, Historic and Forecast Data
- 9.6.2. Latin America by Segment
- 9.6.3. Latin America by Country
- 9.6.4. Brazil
- 9.6.5. Argentina
- 9.6.6. Peru
- 9.6.7. Chile
- 9.6.8. Rest of Latin America
9.7. Middle East & Africa
- 9.7.1. Overview, Historic and Forecast Data
- 9.7.2. Middle East & Africa by Segment
- 9.7.3. Middle East & Africa by Country
- 9.7.4. Saudi Arabia
- 9.7.5. UAE
- 9.7.6. Israel
- 9.7.7. South Africa
- 9.7.8. Rest Of Middle East And Africa

10 . COMPETITIVE LANDSCAPE OF THE BIOPHARMACEUTICALS CONTRACT MANUFACTURING COMPANIES

10.1. Biopharmaceuticals Contract Manufacturing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF BIOPHARMACEUTICALS CONTRACT MANUFACTURING INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Boehringer Ingelheim GmbH
- 11.3.1. Company Overview
- 11.3.2. Financials
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Lonza
- 11.4.1. Company Overview
- 11.4.2. Financials
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Inno Biologics Sdn Bhd
- 11.5.1. Company Overview
- 11.5.2. Financials
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Rentschler Biotechnologie GmbH
- 11.6.1. Company Overview
- 11.6.2. Financials
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. JRS Pharma
- 11.7.1. Company Overview
- 11.7.2. Financials
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. AGC Biologics
- 11.8.1. Company Overview
- 11.8.2. Financials
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. ProBioGen
- 11.9.1. Company Overview
- 11.9.2. Financials
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- 11.10.1. Company Overview
- 11.10.2. Financials
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Toyobo Co., Ltd.
- 11.11.1. Company Overview
- 11.11.2. Financials
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Samsung BioLogics
- 11.12.1. Company Overview
- 11.12.2. Financials
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Thermo Fisher Scientific, Inc.
- 11.13.1. Company Overview
- 11.13.2. Financials
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Binex Co., Ltd.
- 11.14.1. Company Overview
- 11.14.2. Financials
- 11.14.3. Products
- 11.14.4. Recent Developments
11.15. WuXi Biologics
- 11.15.1. Company Overview
- 11.15.2. Financials
- 11.15.3. Products
- 11.15.4. Recent Developments
11.16. AbbVie, Inc.
- 11.16.1. Company Overview
- 11.16.2. Financials
- 11.16.3. Products
- 11.16.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies